Semaglutide 7.2 mg Shows Greater BMI, Cardiometabolic Gains in T2D

New data from the phase 3 STEP UP T2D trial suggest that a higher subcutaneous dose of semaglutide 7.2 mg was associated with numerically greater proportions of patients with obesity and type 2 diabetes (T2D) reaching proposed BMI and waist-to-height ratio (WHtR) treatment targets, as well as low-risk thresholds for key cardiometabolic markers, compared with the 2.4 mg dose or placebo at 72 weeks.

The findings were presented by Carel Le Roux, MBChB, MSC, PhD, as a late-breaking poster at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana.

STEP UP T2D Trial Design and Study Population

STEP UP T2D was a phase 3, randomized, placebo-controlled trial evaluating once-weekly subcutaneous semaglutide 7.2 mg and semaglutide 2.4 mg dose in adults with obesity and T2D. The analysis presented at ADA included 512 participants, including 307 receiving semaglutide 7.2 mg, 103 receiving semaglutide 2.4 mg, and 102 receiving placebo.

The mean T2D duration at baseline was 8.4 years (SD, 6.4), and mean HbA1c was 8.1% (SD, 0.9), reflecting a population with established, moderately uncontrolled diabetes. No participants met the BMI or WHtR treatment targets at baseline, which were defined as a BMI < 27 kg/m2 and a WHtR < 0.53, respectively — thresholds that have been proposed as clinically meaningful goals for obesity management in the context of metabolic risk reduction.

Cardiometabolic outcomes assessed at week 72 included normoglycemia, HDL-cholesterol, blood pressure, and triglycerides, each evaluated against established low-risk reference thresholds.

72 Week Findings From ADA 2026

At week 72, numerically greater proportions of participants in the semaglutide 7.2 mg group achieved the BMI target of < 27 kg/m2, the WHtR target of < 0.53, or both, compared with those receiving semaglutide 2.4 mg or placebo. Of note, the same directional pattern was observed across the cardiometabolic low-risk thresholds, with the 7.2 mg cohort showing numerically higher rates of reaching target ranges for normoglycemia, HDL-cholesterol, blood pressure, and triglycerides.

Findings are consistent with the direction seen in the parent STEP UP trial, which evaluated semaglutide 7.2 mg in participants with obesity but without T2D. However, the investigators noted that overall proportions achieving the anthropometric and cardiometabolic targets were lower in the T2D population than in STEP UP, reflecting the additional metabolic burden and treatment complexity associated with T2D.

Clinical Context: Obesity and T2D as Compounding CVD Risk Factors

Adults with both obesity and T2D represent a population at substantially elevated CVD risk, and achieving clinically meaningful reductions in BMI and central adiposity, reflected by WHtR, has emerged as a treatment goal beyond glycemic control alone. The WHtR threshold of 0.53 and BMI target < 27 kg/m2 have been proposed as more sensitive indicators of cardiometabolic risk than traditional weight-based metrics, particularly in populations with metabolic comorbidities.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved at 2.4 mg weekly (Wegovy, Novo Nordisk) for chronic weight management in adults with obesity or overweight with weight-related comorbidities, and at 1 mg and 2 mg weekly (Ozempic) for glycemic control in T2D and cardiovascular risk reduction.

On March 19, 2026, the US Food and Drug Administration approved higher dose semaglutide injection 7.2 mg to be used along with a reduced calorie diet and increased physical activity to help adults with obesity lose weight and keep it off, provided they have tolerated the 2.4 mg dosage for ≥ 4 weeks and additional weight reduction is clinically indicated. The approval was based on the results from the STEP UP trial program.

The 7.2 mg dose evaluated in the present research represents an investigational escalation intended to assess whether a higher dose can extend the magnitude of weight and metabolic benefit. The data presented at ADA suggest a dose-dependent response pattern, though the absolute gap in target achievement compared with the non-T2D population underscores the challenge of normalizing metabolic parameters in the setting of T2D.

Limitations and Unmet Need in the T2D Population

The investigators acknowledged that despite the dose-dependent numerical advantage observed with semaglutide 7.2 mg, overall BMI and WHtR target achievement in STEP UP T2D remained lower than that seen in STEP UP, which enrolled participants without diabetes. This finding highlights the continued unmet need in a population in which metabolic disease burden, longer T2D duration, and existing CVD risk complicate weight and cardiometabolic normalization.

References

1. Le Roux C, Das S, Harder-Lauridsen NM, et al. STEP UP T2D: Participants Achieving BMI, WHtR, and Cardiometabolic Treatment Targets. Presented at American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, June 5-8, 2026.

2. Ashwell M, Gibson S. Waist-to-height ratio as an indicator of 'early health risk': simpler and more predictive than using a 'matrix' based on BMI and waist circumference. BMJ Open. 2016;6(3):e010159.

3. Brooks A. FDA Approves Higher Dose Semaglutide (Wegovy HD) Injection 7.2 mg for Obesity. HCPLive. March 19, 2026. Accessed June 5, 2026. https://www.hcplive.com/view/fda-approves-higher-dose-semaglutide-wegovy-hd-injection-7-2-mg-for-obesity